# US 2024/0188563 A1 · Catheter lock solutions incorporating nitric oxide releasing liposomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0188563 A1
- Document ID: US20240188563A1
- Status: Published application
- Kind: A1
- Application number: 18/078,694
- Filed: 2022-12-09
- Published: 2024-06-13
- Earliest claimed: 2022-12-09
- Assignees: Becton, Dickinson and Company
- Applicants: Becton, Dickinson and Company
- Inventors: Brendan Laine
- Web page: https://patentgrep.com/patent/US20240188563A1

## CPC

- A01N 33/26: containing nitrogen-to-nitrogen bonds, e.g. azides, diazo-amino compounds, diazonium compounds, hydrazine derivatives
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A01N 25/04: Dispersions, {emulsions, suspoemulsions, suspension concentrates} or gels (foams A01N25/16)
- A01N 41/12: not containing sulfur-to-oxygen bonds, e.g. polysulfides
- A61L 2300/114: Nitric oxide, i.e. NO
- A61L 2300/626: Liposomes, micelles, vesicles
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Catheter lock solutions contain liposomes which encapsulate a nitric oxide releasing precursor material. The catheter lock solutions release nitric oxide under physiologic conditions to provide antithrombotic and antimicrobial properties. The liposomes may be lyophilized for stable storage to maintain their nitric oxide releasing capacity. A kit for preparing a catheter lock solution includes a quantity of lyophilized liposomes which encapsulate a nitric oxide releasing precursor material and a volume of an aqueous rehydrating solution. A catheter lock solution may be prepared by rehydrating a quantity of lyophilized liposomes which encapsulate a nitric oxide releasing precursor material with an aqueous rehydrating solution in a volume sufficient to fill a catheter.

## Claims

### Claim 1

An aqueous catheter lock solution comprising liposomes, wherein the liposomes encapsulate a nitric oxide releasing precursor material.

### Claim 2 (depends on 1)

The catheter lock solution according to claim 1, wherein the liposomes have an outer membrane comprising a lipid material and cholesterol.

### Claim 3 (depends on 2)

The catheter lock solution according to claim 2, wherein the lipid material and cholesterol are present in an approximately 1:1 molar ratio.

### Claim 4 (depends on 2)

The catheter lock solution according to claim 2, wherein the lipid material comprises a phosphocholine material.

### Claim 5 (depends on 4)

The catheter lock solution according to claim 4, wherein the phosphocholine material comprises dipalmitolylphosphatidylcholine (DPPC).

### Claim 6 (depends on 1)

The catheter lock solution according to claim 1, wherein the liposomes have an outer membrane comprising a lipid material selected from dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dipalmitoyltrimethylammoniumpropane (DPTAP), dipalmitoylphosphatidylglycerol (DPPG), and mixtures thereof.

### Claim 7 (depends on 1)

The catheter lock solution according to claim 1, wherein the nitric oxide releasing precursor material is selected from N-diazeniumdiolate-modified dipropylenetriamine (DPTA/NO), N-diazeniumdiolate-modified diethylamine (DEA/NO), N-diazeniumdiolate-modified diethylenetriamine (DETA/NO), N-diazeniumdiolate-modified N-propyl-1,3-propanediamine (PAPA/NO), N-diazeniumdiolate-modified L-proline (PROLI/NO), S-nitrosothiol (RSNO), S-nitrosoglutathione (GSNO), S-nitroso-N-acetyl penicillamine (SNAP), N-diazeniumdiolate-modified spermine (SPER/NO), and mixtures thereof.

### Claim 8 (depends on 1)

The catheter lock solution according to claim 1, wherein the nitric oxide releasing precursor material comprises N-diazeniumdiolate-modified spermine (SPER/NO).

### Claim 9 (depends on 1)

The catheter lock solution according to claim 1, wherein the liposomes have an outer membrane comprising a lipid material and cholesterol, wherein the lipid material is selected from dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dipalmitoyltrimethylammoniumpropane (DPTAP), dipalmitoylphosphatidylglycerol (DPPG), and mixtures thereof, wherein the nitric oxide releasing precursor material is selected from N-diazeniumdiolate-modified dipropylenetriamine (DPTA/NO), N-diazeniumdiolate-modified diethylamine (DEA/NO), N-diazeniumdiolate-modified diethylenetriamine (DETA/NO), N-diazeniumdiolate-modified N-propyl-1,3-propanediamine (PAPA/NO), N-diazeniumdiolate-modified L-proline (PROLI/NO), S-nitrosothiol (RSNO), S-nitrosoglutathione (GSNO), S-nitroso-N-acetyl penicillamine (SNAP), N-diazeniumdiolate-modified spermine (SPER/NO), and mixtures thereof.

### Claim 10 (depends on 9)

The catheter lock solution according to claim 9, wherein the lipid material and cholesterol are present in an approximately 1:1 molar ratio, the lipid material comprises dipalmitolylphosphatidylcholine (DPPC), and the nitric oxide releasing precursor material comprises N-diazeniumdiolate-modified spermine (SPER/NO).

### Claim 11 (depends on 1)

The catheter lock solution according to claim 1, wherein the nitric oxide releasing precursor material has a nitric oxide releasing capacity, and wherein the nitric oxide releasing precursor retains at least 80% of its nitric oxide releasing capacity after three months of storage.

### Claim 12 (depends on 1)

The catheter lock solution according to claim 1, wherein the nitric oxide releasing precursor material is dissolved in an aqueous solution having a basic pH in the range from about 7.1 to about 13.

### Claim 13 (depends on 1)

A method for preparing the catheter lock solution according to claim 1, comprising:
obtaining a quantity of lyophilized liposomes which encapsulate a nitric oxide releasing precursor material; and
rehydrating the lyophilized liposomes to form the catheter lock solution.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the lyophilized liposomes have an outer membrane comprising a lipid material and cholesterol, wherein the lipid material is selected from dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dipalmitoyltrimethylammoniumpropane (DPTAP), dipalmitoylphosphatidylglycerol (DPPG), and mixtures thereof, wherein the nitric oxide releasing precursor material is selected from N-diazeniumdiolate-modified dipropylenetriamine (DPTA/NO), N-diazeniumdiolate-modified diethylamine (DEA/NO), N-diazeniumdiolate-modified diethylenetriamine (DETA/NO), N-diazeniumdiolate-modified N-propyl-1,3-propanediamine (PAPA/NO), N-diazeniumdiolate-modified L-proline (PROLI/NO), S-nitrosothiol (RSNO), S-nitrosoglutathione (GSNO), S-nitroso-N-acetyl penicillamine (SNAP), N-diazeniumdiolate-modified spermine (SPER/NO), and mixtures thereof.

### Claim 15 (depends on 1)

A kit for preparing the catheter lock solution according to claim 1, comprising:
a quantity of lyophilized liposomes which encapsulate a nitric oxide releasing precursor material; and
a quantity of an aqueous rehydrating solution.

### Claim 16 (depends on 15)

The kit according to claim 15, wherein the lyophilized liposomes have an outer membrane comprising a lipid material and cholesterol, wherein the lipid material is selected from dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dipalmitoyltrimethylammoniumpropane (DPTAP), dipalmitoylphosphatidylglycerol (DPPG), and mixtures thereof, wherein the nitric oxide releasing precursor material is selected from N-diazeniumdiolate-modified dipropylenetriamine (DPTA/NO), N-diazeniumdiolate-modified diethylamine (DEA/NO), N-diazeniumdiolate-modified diethylenetriamine (DETA/NO), N-diazeniumdiolate-modified N-propyl-1,3-propanediamine (PAPA/NO), N-diazeniumdiolate-modified L-proline (PROLI/NO), S-nitrosothiol (RSNO), S-nitrosoglutathione (GSNO), S-nitroso-N-acetyl penicillamine (SNAP), N-diazeniumdiolate-modified spermine (SPER/NO), and mixtures thereof.

### Claim 17

A method of preparing liposomes which encapsulate a nitric oxide releasing precursor material, comprising:
combining a lipid material and cholesterol in an organic solvent for form an organic phase, wherein the lipid material and cholesterol are present in an approximately 1:1 molar ratio;
adding an aqueous solution comprising a nitric oxide releasing precursor material to the organic phase; and
evaporating the organic solvent, causing liposomes to form and encapsulate the nitric oxide releasing precursor material.

### Claim 18 (depends on 17)

The method of preparing liposomes according to claim 17, wherein the organic solvent is selected from chloroform, methanol, diethyl ether, isopropyl ether, cyclohexane, ethanol, and mixtures thereof.

### Claim 19 (depends on 17)

The method of preparing liposomes according to claim 17, wherein the lipid material comprises dipalmitolylphosphatidylcholine (DPPC) and the nitric oxide releasing precursor material comprises N-diazeniumdiolate-modified spermine (SPER/NO).

### Claim 20 (depends on 17)

The method of preparing liposomes according to claim 17, wherein the aqueous solution has a basic pH in the range from about 7.1 to about 13.

### Claim 21 (depends on 20)

The method of preparing liposomes according to claim 20, wherein the aqueous solution pH is adjusted with sodium hydroxide.

### Claim 22 (depends on 17)

The method of preparing liposomes according to claim 17, further comprising the step of lyophilizing the liposomes.

### Claim 23 (depends on 22)

The method of preparing liposomes according to claim 22, wherein the nitric oxide releasing precursor material has a nitric oxide releasing capacity, and wherein the nitric oxide releasing precursor retains at least 80% of its nitric oxide releasing capacity after three months of storage.
